Fibrosis Lung
10
3
3
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (10)
Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis
Western Sweden Systemic Sclerosis Project
AI Assisted Detection of Chest X-Rays
Automated Oxygen Titration During Walking in Patients With Lung Fibrosis (OXYWILD)
Practice of Oxygenation and Respiratory Support During Fiberoptic Bronchoscopy
Identifying Unique Pathogenic Macrophages in Systemic Sclerosis-ILD
FIBRotic Interstitial Lung Disease With Nocturnal hypOXaemia and EXercise Induced desaTuRAtion
Effects of Exercise Training on Respiratory Performance in Patients With Fibrosing Interstitial Lung Diseases
Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia
Research of Burden of Interstititial Lung Diseases in Turkey